Comerica Bank’s Atara Biotherapeutics ATRA Stock Holding History

Comerica Bank’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$160	–	3734
2023 Q3	$160	Buy	+4	New	+$178	﹤0.01%	3766

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Comerica Bank's ATRA Position: Q4 2023 in Review

Comerica Bank sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 4 shares — an estimated $160 sold.

Comerica Bank first reported a position in ATRA in Q3 2023 and held it in 1 quarter. The position peaked at $160 in Q3 2023. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

Comerica Bank reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
Comerica Bank sold 4 Atara Biotherapeutics shares in Q4 2023, an estimated $160.
Comerica Bank first reported a position in Atara Biotherapeutics in Q3 2023 and held it in 1 quarter.
Comerica Bank's Atara Biotherapeutics position peaked at $160 in Q3 2023.
90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Comerica Bank's 13F filing for Q4 2023, filed 14 Feb 2024.